She highlights anito-cell's new efficacy data, and a safety profile that continues to look clean. Plus, she thinks a CD19 + CD20 dual antigen CAR-T could be best in class in the future, and why Kite acquired an in vivo CAR-T company in August for $350M.

Founder and CEO Adam Rosenthal describes the unmet need for patients with this condition, and walks us through VGA039, a protein S modulator.

He says he is confident in the commercial leadership profile that Carvykti has established, and walks us through potential follow-on pipeline programs.

Co-Founders Luke Evnin and Steven St. Peter describe the idea behind the firm, the value in partnering with philanthropies who know these diseases best, and why I&I is going through such a revolution currently.

Founder and CEO Bent Jakobsen describes the science behind the platform, which he believes is unique in that it is delivered systemically, but is designed to bypass healthy tissue and only target tumor cells (without the need for screening). It targets the integrin αvβ6.

CEO Iain Foulkes describes the impact Cancer Research Horizons has already made (14 marketed medicines), which has allowed more than £600M in royalty income to be reinvested in research. He describes the structure of the organization, a new startup fund, and some notable investments.

He also goes over the company's programs in aesthetics, liver disease, and oncology.

The data has been accepted for an oral presentation on Monday, December 8 and will be followed by a company webcast with more info.

He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes.

He discusses the rationale behind the firm's asset-centric approach and highlights Vicebio as an example of how it works. Plus, his take on the current investment environment.